Storia in 7 fonti

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo2 g fa

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

originale

Timeline cronologica

giovedì 13 agosto 2026·medpagetoday.com
FDA Approves First CELMoD Drug for Multiple Myeloma
Iberdomide indicated as part of combination regimen for relapsed or refractory disease
giovedì 13 agosto 2026·morningstar.com
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and…
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for…

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

Confronto fonti

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

Timeline cronologica

FDA Approves First CELMoD Drug for Multiple Myeloma

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and…

Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination…

Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma

FDA approves Bristol Myers’ multiple myeloma successor

FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class

FDA approves Bristol Myers’ multiple myeloma successor

Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class

Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)